Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA7 | P43166 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739985 | 1.00 | NR1H2 (0.49) | NR1H2NR1H3CA12CA1CA2 | |
| SCHEMBL23618033 | 0.84 | NR1H2 (0.47) | NR1H2NR1H3CA12CA1CA2 | |
| SCHEMBL23096154 | 0.80 | CA12 (0.41) | NR1H2NR1H3CA12CA1CA2 | |
| SCHEMBL4974794 | 0.79 | NPSR1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30940533 | 0.79 | NPSR1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18560495 | 0.73 | KDM4E (0.47) | NR1H2NR1H3CA12CA1CA2 | |
| SCHEMBL17194938 | 0.72 | MEN1 (0.38) | SMN1; SMN2CYP3A4ALDH1A1KDM4EMAPK1 | |
| SCHEMBL8630212 | 0.72 | CA12 (0.43) | NR1H2NR1H3CA12CA1CA2 | |
| SCHEMBL29739916 | 0.71 | GLP1R (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4019772 | 0.71 | GLP1R (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565487-B2 | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2026-01-01 | — | — | US | disclosed |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | InventisBio Co., Ltd. (CN) | 2025-12-09 | — | — | US | disclosed |
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4551559-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119954772-A | Heteroaryl compounds, methods of making and uses thereof | 益方生物科技(上海)股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119954775-A | Heteroaryl compounds, methods of making and uses thereof | 益方生物科技(上海)股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240382477-A1 | NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| US-20240343747-A1 | Heteroaryl compounds as inhibitors of TYK2, composition and application thereof | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2024-10-17 | — | — | US | disclosed |
| CN-111315737-B | Heteroaryl compounds substituted with sulfone pyridinylalkylamides | 百时美施贵宝公司 | 2024-06-18 | — | — | CN | disclosed |
| US-9505748-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-29 | — | — | US | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| US-20150299183-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-22 | — | — | US | disclosed |
| WO-2014074661-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1689406-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1689406-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005051906-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382477-A1 | NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND | NNMT, NOD1, NOD2 | NR1H2 2780/4885NR1H3 3276/4885CA12 4362/4885 |
| US-20150299183-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | NR1H2 1833/4885NR1H3 2123/4885CA12 2379/4885 |
| US-20240343747-A1 | Heteroaryl compounds as inhibitors of TYK2, composition and application thereof | TYK2, PTK2B, BTK | NR1H2 1472/4885NR1H3 1447/4885CA12 4780/4885 |
| US-12565487-B2 | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide | TYK2, DYRK3, DYRK4 | NR1H2 4411/4885NR1H3 4536/4885CA12 2615/4885 |
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | JAK1, JAK2, TYK2 | NR1H2 826/4885NR1H3 800/4885CA12 3342/4885 |
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | NR1H2 2204/4885NR1H3 2264/4885CA12 2843/4885 |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | NR1H2 536/4885NR1H3 605/4885CA12 4872/4885 |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | TYK2, IL2, IL23R | NR1H2 888/4885NR1H3 795/4885CA12 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.